within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03A_HormonalContraceptivesForSystemicUse.G03AC05_Megestrol;

model Megestrol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.32,
    Cl = 4.1666666666666667e-07,
    adminDuration = 600,
    adminMass = 160 / 1000000,
    adminCount = 1,
    Vd = 0.05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013833333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Megestrol</td></tr><tr><td>ATC code:</td><td>G03AC05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>160</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>50</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.5</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Megestrol is a synthetic progestin, primarily used as megestrol acetate to stimulate appetite and promote weight gain in patients with anorexia, cachexia, or significant weight loss due to cancer or AIDS. It has also been used in the palliative treatment of advanced breast and endometrial cancers. Megestrol acetate is approved and used in clinical practice today for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics parameters estimated for healthy adult subjects after oral administration, as published data are scarce. Estimates are derived from pharmacokinetic summaries and reviews where explicit PK parameters are not fully detailed.</p><h4>References</h4><ol><li><p>Kim, YH, et al., &amp; Bae, KS (2015). Tolerability and pharmacokinetics of two formulations of megestrol acetate under fed conditions in healthy volunteers. <i>Clinical therapeutics</i> 37(2) 439–447. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2014.09.022\">10.1016/j.clinthera.2014.09.022</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25450470/\">https://pubmed.ncbi.nlm.nih.gov/25450470</a></p></li><li><p>Post, TM, et al., &amp; de Greef, R (2016). Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation. <i>Contraception</i> 93(2) 133–138. DOI:<a href=\"https://doi.org/10.1016/j.contraception.2015.08.017\">10.1016/j.contraception.2015.08.017</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26365792/\">https://pubmed.ncbi.nlm.nih.gov/26365792</a></p></li><li><p>Markman, M, et al., &amp; Belinson, J (2000). Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 6(11) 4201–4204. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11106232/\">https://pubmed.ncbi.nlm.nih.gov/11106232</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G03AC05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Megestrol;
